遺伝子発現解析の世界市場：DNAマイクロアレイ、PCR、NGS、SAGE、ノーザンブロッティング...市場調査レポートについてご紹介

1 Introduction (Page No. – 17)
1.1 Objectives Of theStudy
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for theStudy
1.4 Currency
1.5 Package Size
1.6 Limitations
1.7 Stakeholders

2 Research Methodology (Page No. – 21)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.3 Key Data From Secondary Sources
2.3.1 Primary Research
2.3.2 Key Industry Insights
2.4 Key Data From Primary Sources
2.5 Key Insights From Primary Sources
2.6 Market Size Estimation Methodology
2.7 Market Forecast Methodology
2.8 Market Data Validation and Triangulation
2.9 Assumptions for theStudy

3 Executive Summary (Page No. – 30)
3.1 Introduction

4 Premium Insights (Page No. – 35)
4.1 Global Gene Expression Analysis Market Overview
4.2 Geographic Analysis: Gene Expression Analysis Market, By Product
4.3 Geographical Snapshot Of the Gene Expression Analysis Market
4.4 Gene Expression Analysis Instruments Market Size, By Technology, 2015 vs 2020

5 Industry Insights (Page No. – 39)
5.1 Value Chain Analysis
5.2 Porter’s Five Forces Analysis
5.2.1 Threat Of New Entrants
5.2.2 Threat Of Substitutes
5.2.3 Bargaining Power Of Buyers
5.2.4 Bargaining Power Of Suppliers
5.2.5 Competitive Rivalry Among Existing Firms
5.3 Industry Views/Insights/ Industry Talks

6 Market Overview (Page No. – 42)
6.1 Introduction
6.2 Market Segmentation
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Decreasing Cost Of Sequencing
6.3.1.2 Growth in The Number Of Cancer Patients
6.3.1.3 Availability Of Government Funding
6.3.1.4 Use Of Microarray Technology to Aid Gene Expression Studies
6.3.1.5 Sbs Technology to Aid More Detailed Cancer Studies
6.3.1.6 Availability Of Gene Expression Databases
6.3.2 Restraints
6.3.2.1 High Cost Of Instruments
6.3.2.2 Shortage Of Trained Professionals
6.3.3 Opportunities
6.3.3.1 Emerging Countries to Provide Growth Opportunities
6.3.3.1.1 Collaborative Efforts in China Aimed at Improving theQuality Of Healthcare
6.3.3.1.2 Strong Focus on theBiotechnology Sector in India
6.3.3.1.3 Government Funding for Research in Brazil
6.3.3.2 Growing Government Focus on Personalized Medicine
6.3.4 Challenge
6.3.4.1.1 Currency Devaluation

7 Gene Expression Analysis Market, By Consumables (Page No. – 51)
7.1 Introduction
7.2 Reagents
7.3 Dna Chips

8 Gene Expression Analysis Instruments Market, By Technology (Page No. – 57)
8.1 Introduction
8.2 Polymerase Chain Reaction (PCR)
8.3 Next-Generation Sequencing (NGS)
8.3.1 Cost and Speed Of NGS
8.3.2 Substitution Of Microarray Technology By NGS
8.3.3 Research Laboratories and Academicians Promoting NGS
8.3.4 Global Alliances Among Leading Research Institutes to Assist Drug Discovery and Increase theDemand for NGS
8.4 Dna Microarray
8.5 Others
8.5.1 Serial Analysis Of Gene Expression
8.5.2 Northern Blotting

9 Gene Expression Analysis Market, By Service (Page No. – 65)
9.1 Introduction
9.2 Gene Expression Profiling Services
9.2.1 Sequencing Services
9.2.2 Other Services
9.3 Bioinformatics Solutions

10 Gene Expression Analysis Market, By Applications (Page No. – 72)
10.1 Introduction
10.2 Research
10.3 Drug Discovery
10.4 Diagnostics
10.5 Other Applications

11 Gene Expression Market, By Region (Page No. – 78)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Development Of Gene Therapy in theU.S.
11.2.1.2 Focus on Gene Expression Studies to Improve Quality Of Patient Care
11.2.1.3 Precision Medicine Initiative
11.2.1.4 Government Funding
11.2.2 Canada
11.2.2.1 Gene Expression Profiling Tests in Canada
11.2.2.2 Government Initiatives
11.2.2.3 Government Funding for NGS
11.3 Europe
11.3.1 U.K.
11.3.1.1 U.K. Project to Sequence 100,000 Genomes
11.3.1.2 Government Funding in theU.K.
11.3.2 Germany
11.3.2.1 Conferences in Germany
11.3.3 France
11.3.3.1 Introduction Of Non-Invasive Prenatal Testing in France
11.3.4 Rest Of Europe (RoE)
11.3.4.1 Turkey to Offer Growth Opportunities
11.3.4.2 Focus on Gene Therapy
11.3.4.3 Increasing Funding for Molecular Diagnostics in Europe
11.3.4.4 Investments in Rare Disease Research
11.4 Asia Pacific
11.4.1 China
11.4.1.1 Western Partnerships in China Aimed at Improving Healthcare
11.4.1.2 Domestic Manufacturing Of Sequencing Systems in China
11.4.1.3 Efforts Of Bgi to Boost theChinese Market for Gene Expression
11.4.1.4 Gene Expression Signature for Quality Control Of Traditional Chinese Medicines
11.4.2 Japan
11.4.2.1 Japanese Government’s Focus on Cancer
11.4.2.2 Research Efforts in Japan
11.4.3 Korea, Australia, and New Zealand
11.4.3.1 Need to Develop Treatments for Animals
11.4.3.2 Flourishing Bioresearch Centers & Financial Support in Australia
11.4.4 Rest Of Asia-Pacific (RoAPAC)
11.4.4.1 Gene Expression Tests Gaining Popularity in India
11.4.4.2 theRise Of the Indian Gene Expression Analysis Market
11.4.4.3 Regular Funding From theIndian Government, an Impetus to the NGS Market
11.4.4.4 Singapore’s Strong Focus on Neurodegenerative Diseases
11.5 Rest Of theWorld (RoW)
11.5.1.1 Sequencing Of 100,000 Genomes in theSaudi Arabia
11.5.1.2 Focus on Hiv/Aids Genetic Research in Africa
11.5.1.3 South American Countries Focus on Genomic Research to Improve Public Health
11.5.1.4 Bioinformatics & Biotechnology Research in Latin America to Boost The Demand for NGS Instruments & Services

12 Competitive Landscape (Page No. – 115)
12.1 Overview
12.2 Market Share Analysis
12.2.1 Thermo Fisher Scientific
12.2.2 Illumina, Inc.
12.2.3 Bio-Rad Laboratories
12.2.4 Qiagen N.V.
12.3 Competitive Situation and Trends
12.3.1 New Product Launches
12.3.2 Collaborations, Agreements, and Partnerships
12.3.3 Acquisitions
12.3.4 Other Strategies

13 Company Profiles (Page No. – 122)
13.1 Introduction
13.2 Thermo Fisher Scientific, Inc.
13.3 Qiagen N.V.
13.4 Illumina, Inc.
13.5 Bio-Rad Laboratories, Inc.
13.6 F. Hoffmann-La Roche Ltd. (Roche)
13.7 Agilent Technologies, Inc.
13.8 Affymetrix, Inc.
13.9 GE Healthcare
13.10 Perkinelmer, Inc.
13.11 Oxford Gene Technology

*Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case Of Unlisted Companies.

14 Appendix (Page No. – 157)
14.1 Discussion Guide
14.2 Company Developments (2013-2015)
14.2.1 Thermo Fisher Scientific, Inc.
14.2.2 Qiagen N.V.
14.2.3 Illumina Inc.
14.2.4 Roche
14.2.5 Bio-Rad Laboratories
14.2.6 Agilent Technologies, Inc.
14.2.7 Affymetrix
14.2.8 GE Healthcare
14.2.9 Perkinelmer, Inc.
14.2.10 Oxford Gene Technology
14.3 Introducing RT: Real-Time Market Intelligence
14.4 Available Customizations
14.5 Related Reports